We are analyzing https://link.springer.com/chapter/10.1007/978-3-642-81488-4_30.

Title:
The Rediscovery of DON (6-Diazo-5-oxo-L-norleucine) | SpringerLink
Description:
DON (6-diazo-5-oxo-l-norleucine) and azotomycin are glutamine antagonists that were tested in human malignancies in the 1950s. Azotomycin demonstrated significant activity in colorectal cancer. DON is probably the active form of azotomycin. Recent impressive results...
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Mobile Technology & AI

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 8,149,968 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

cancer, google, scholar, don, pubmed, cas, article, chapter, azotomycin, privacy, cookies, content, publish, research, diazooxolnorleucine, muggia, human, clinical, chemotherapy, data, information, search, results, tumor, preview, access, york, study, log, journal, chemo, immunopharmacology, catane, recent, glutamine, activity, colorectal, phase, download, vivo, res, cooney, disease, chemother, rep, berlin, heidelberg, springer, optional, personal,

Topics {✒️}

6-dia- zo-5-oxo-l-norleucine 6-diazo-5-oxo-l-norleucine privacy choices/manage cookies neoplastic mouse tissues cx-2 colon tumor download preview pdf l-asparaginase synthetase hôpital paul-brousse human tumor xenografts chapter cancer chemo colorectal cancer cells cancer chemotherapy ii european economic area long-lasting reduction triazine mimic antibiotics dna-binding implications hollow fiber assay von hoff dd davis hl jr med clin north initial therapeutic observations 10th international congress journal finder publish spheroids article 02 conditions privacy policy human neoplastic disease phase ii study assoc cancer res previous clinical data accepting optional cookies book series 5-fluorouracil-doxorubicin combination ovejera aa cancer research main content log impressive activity rosenbluth rj cancer chemo clinical study recent impressive results check access ethics access comparative effect bronchogenic carcinoma permissions reprints colorectal cancer heidelberg journal publish personal data privacy policy

Schema {🗺️}

ScholarlyArticle:
      headline:The Rediscovery of DON (6-Diazo-5-oxo-L-norleucine)
      pageEnd:263
      pageStart:258
      image:https://media.springernature.com/w153/springer-static/cover/book/978-3-642-81488-4.jpg
      genre:
         Medicine
         Medicine (R0)
      isPartOf:
         name:Cancer Chemo- and Immunopharmacology
         isbn:
            978-3-642-81488-4
            978-3-642-81490-7
         type:Book
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:D. L. Kisner
            affiliation:
            type:Person
            name:R. Catane
            affiliation:
            type:Person
            name:F. M. Muggia
            affiliation:
            type:Person
      keywords:Human Tumor Xenograft, Orotic Acid, Carbamyl Phosphate, Daily Dose Schedule, Carbamyl Phosphate Synthetase
      description:DON (6-diazo-5-oxo-l-norleucine) and azotomycin are glutamine antagonists that were tested in human malignancies in the 1950s. Azotomycin demonstrated significant activity in colorectal cancer. DON is probably the active form of azotomycin. Recent impressive results for both of these agents in human tumor xenografts (especially the CX-2 colon tumor) have stimulated renewed clinical interest in DON, the more readily available agent. DON mechanism of action, clinical pharmacology, previous clinical data, and current phase I studies are discussed.
      datePublished:1980
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Cancer Chemo- and Immunopharmacology
      isbn:
         978-3-642-81488-4
         978-3-642-81490-7
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:D. L. Kisner
      affiliation:
      name:R. Catane
      affiliation:
      name:F. M. Muggia
      affiliation:
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(64)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js

5.17s.

LINK . SPRINGER . COM {}